Monod Bio, a Seattle, WA-based life sciences company developing custom diagnostic biosensors that emit light to detect specific biomolecules of interest, raised $25M in Seed funding.
The round was led by Matrix Capital, with participation from Global Health Investment Corporation, Cercano Management, The Washington Research Foundation, Boom Capital Ventures, Sahsen Ventures, and Pack Ventures.
The company intends to use the funds to advance its platform for the rapid development of one-step biosensors and reporter proteins to detect targets for applications in biotechnology and medicine, and to double the size of its research and engineering teams in the coming 18 months.
Co-founded by Daniel-Adriano Silva, Ph.D., CEO, Alfredo Quijano Rubio, Ph.D, Chief Scientific Officer, David Shoultz, Ph.D., M.B.A., Chief Operating Officer, and David Baker, Scientific Advisor, Monod Bio is a life science company that designs custom de novo protein-based biosensors that emit light when they recognize its target. The company’s biosensor platform technology uses computational protein engineering to create modular biosensing nanoswitches that enable rapid, sensitive, and cost-effective analytical assays. Biosensors are instruments that detect the presence of specific molecules, even at trace concentrations. The sensors are built from de novo engineered proteins developed using software from the Institute of Protein Design (IPD) at the University of Washington School of Medicine.
FinSMEs
16/08/2022